Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 vs Durvalumab in Unresectable Stage III NSCLC
NCT03840902Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 2 trial of bintrafusp alfa in non-small cell lung cancer (NSCLC), sponsored by EMD Serono. Started Apr 2019; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03840902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840902.